Home  |  Contact

UniProtKB/Swiss-Prot Q14498: Variant p.Gly268Glu

RNA-binding protein 39
Gene: RBM39
Variant information

Variant position:  268
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  Unclassified
The variants are classified into three categories: Disease, Polymorphism and Unclassified.
  • Disease: Variants implicated in disease according to literature reports.
  • Polymorphism: Variants not reported to be implicated in disease.
  • Unclassified: Variants with uncertain implication in disease according to literature reports. Evidence against or in favor of a pathogenic role is limited and/or conflicting.

Residue change:  From Glycine (G) to Glutamate (E) at position 268 (G268E, p.Gly268Glu).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from glycine (G) to medium size and acidic (E)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -2
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  Associated with resistance to anticancer indisulam.
Any additional useful information about the variant.



Sequence information

Variant position:  268
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  530
The length of the canonical sequence.

Location on the sequence:   GPMRLYVGSLHFNITEDMLR  G IFEPFGRIESIQLMMDSETG
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         GPMRLYVGSLHFNITEDMLRGIFEPFGRIESIQLMMDSETG

Mouse                         GPMRLYVGSLHFNITEDMLRGIFEPFGRIESIQLMMDSETG

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 2 – 530 RNA-binding protein 39
Domain 250 – 328 RRM 2
Helix 263 – 270


Literature citations

Anticancer sulfonamides target splicing by inducing RBM39 degradation via recruitment to DCAF15.
Han T.; Goralski M.; Gaskill N.; Capota E.; Kim J.; Ting T.C.; Xie Y.; Williams N.S.; Nijhawan D.;
Science 356:0-0(2017)
Cited for: FUNCTION; UBIQUITINATION; VARIANTS LEU-265; ARG-268; GLU-268; TRP-268; VAL-268; GLN-271; GLY-271 AND SER-272; CHARACTERIZATION OF VARIANTS LEU-265; ARG-268; TRP-268; VAL-268; GLN-271 AND SER-272;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.